Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Cardiovascular

Song Gao1, Keneilwe Kenny Kaudimba1, Shanshan Guo1

  • 1School of Kinesiology, Shanghai University of Sport, Shanghai, China.

Frontiers in Physiology
|September 9, 2020
PubMed

Insights

Transient Receptor Potential Ankyrin 1 (TRPA1) channels in the vascular endothelium show complex roles in cardiovascular diseases. Understanding TRPA1

Area of Science:

  • Cardiovascular physiology and pharmacology
  • Ion channel biology
  • Endothelial function

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of mortality.
  • Hypertension, metabolic disorders, and smoking are key risk factors for CVDs.
  • Targeting novel pathways is crucial for effective CVD drug development.

Purpose of the Study:

  • To review the structural and functional characteristics of Transient Receptor Potential Ankyrin 1 (TRPA1).
  • To explore the role of TRPA1 in vascular physiology and its association with cardiovascular diseases.
  • To summarize evidence linking TRPA1 to CVD risk factors.

Main Methods:

  • Literature review of existing studies on TRPA1.
  • Analysis of TRPA1 expression in vascular endothelium.
  • Synthesis of data on TRPA1's role in atherosclerosis, myocardial fibrosis, heart failure, and arrhythmia.

Main Results:

  • TRPA1 channels are expressed in the vascular endothelium, a key player in CVDs.
  • TRPA1 activation has beneficial effects on atherosclerosis.
  • TRPA1 activation negatively impacts myocardial fibrosis and heart failure.

Conclusions:

  • TRPA1 presents a complex, context-dependent role in cardiovascular pathophysiology.
  • TRPA1 is a potential therapeutic target for cardiovascular diseases, with differential effects.
  • Further research into TRPA1 modulation could yield novel CVD treatments.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
5.4K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.3K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.5K